新型恶唑烷酮类药物DA-7867对需氧革兰氏阳性菌的体外和体内活性
In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria.
作者信息
Yoon Eun Jeong, Jo Yeong Woo, Choi Sung Hak, Lee Tae Ho, Rhee Jae Keol, Yoo Moohi, Shim Mi Ja, Choi Eung Chil
机构信息
Department of Microbiology, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, San 56-1, Shillim-9 dong, Kwanak-gu, Seoul 151-742, Korea.
出版信息
Antimicrob Agents Chemother. 2005 Jun;49(6):2498-500. doi: 10.1128/AAC.49.6.2498-2500.2005.
Abstract
In vitro and in vivo activities of DA-7867 were assessed against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and penicillin-resistant Streptococcus pneumoniae. All isolates were inhibited by DA-7867 at <or=0.78 microg/ml, a four-times-lower concentration than that of inhibition by linezolid. For murine infection models, DA-7867 also exhibited greater efficacy than linezolid against all isolates tested.
摘要
对DA-7867针对耐甲氧西林金黄色葡萄球菌、耐万古霉素肠球菌和耐青霉素肺炎链球菌的体外和体内活性进行了评估。所有分离株均被DA-7867在≤0.78微克/毫升的浓度下抑制，该浓度比利奈唑胺的抑制浓度低四倍。对于小鼠感染模型，DA-7867对所有测试分离株也表现出比利奈唑胺更高的疗效。
相似文献
1
In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria.新型恶唑烷酮类药物DA-7867对需氧革兰氏阳性菌的体外和体内活性
Antimicrob Agents Chemother. 2005 Jun;49(6):2498-500. doi: 10.1128/AAC.49.6.2498-2500.2005.
2
Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.2006年Zyvox效力与抗菌谱年度评估项目结果：利用来自16个国家的临床分离菌株对利奈唑胺进行的活性及抗菌谱分析
Diagn Microbiol Infect Dis. 2007 Oct;59(2):199-209. doi: 10.1016/j.diagmicrobio.2007.06.001.
3
Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.台湾地区达托霉素、糖肽类、利奈唑胺和替加环素对革兰氏阳性菌血液分离株的杀菌活性比较
Clin Microbiol Infect. 2008 Feb;14(2):124-9. doi: 10.1111/j.1469-0691.2007.01888.x. Epub 2007 Dec 10.
4
Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.2002年利奈唑胺药敏模式趋势：来自全球Zyvox效力与谱年度评估计划的报告
Diagn Microbiol Infect Dis. 2005 May;52(1):53-8. doi: 10.1016/j.diagmicrobio.2004.12.013.
5
Efficacy and safety of linezolid in liver transplant patients.利奈唑胺在肝移植患者中的疗效与安全性。
Transpl Infect Dis. 2011 Aug;13(4):353-8. doi: 10.1111/j.1399-3062.2011.00617.x. Epub 2011 Feb 28.
6
Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.利奈唑胺药敏模式趋势：2002 - 2003年全球Zyvox年度效力与谱评估（ZAAPS）项目报告
Int J Antimicrob Agents. 2005 Jul;26(1):13-21. doi: 10.1016/j.ijantimicag.2005.02.019.
7
Surveillance of linezolid resistance in Germany, 2001-2002.2001 - 2002年德国利奈唑胺耐药性监测
Clin Microbiol Infect. 2005 Jan;11(1):39-46. doi: 10.1111/j.1469-0691.2004.01036.x.
8
Use of linezolid in pediatrics: a critical review.利奈唑胺在儿科中的应用：一项关键性评价。
Int J Infect Dis. 2010 Aug;14(8):e638-48. doi: 10.1016/j.ijid.2009.10.002. Epub 2010 Jan 27.
9
In vitro and in vivo antibacterial evaluation of DRF 8417, a new oxazolidinone.新型恶唑烷酮类药物DRF 8417的体外和体内抗菌评估
J Antimicrob Chemother. 2007 Jul;60(1):159-61. doi: 10.1093/jac/dkm116. Epub 2007 Apr 21.
10
Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.2004 年至 2009 年期间，在美国进行的替加环素评估和监测试验（TEST）中收集的革兰氏阳性分离株对替加环素和利奈唑胺的敏感性。
Clin Ther. 2011 Dec;33(12):1964-73. doi: 10.1016/j.clinthera.2011.10.010. Epub 2011 Nov 10.
引用本文的文献
1
Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones.恶唑烷酮类对哺乳动物线粒体蛋白质合成的抑制作用。
Antimicrob Agents Chemother. 2006 Jun;50(6):2042-9. doi: 10.1128/AAC.01411-05.
本文引用的文献
1
Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).哨兵抗菌监测计划（1997 - 2002年）血流感染分离株的发生率及抗菌药物耐药模式比较
Diagn Microbiol Infect Dis. 2004 Sep;50(1):59-69. doi: 10.1016/j.diagmicrobio.2004.05.003.
2
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.美国医院的医院获得性血流感染：来自一项全国性前瞻性监测研究的24179例病例分析。
Clin Infect Dis. 2004 Aug 1;39(3):309-17. doi: 10.1086/421946. Epub 2004 Jul 15.
3
Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: intestinal first-pass effect.新型恶唑烷酮类药物DA-7867经静脉或口服给予大鼠后的药代动力学：肠道首过效应
Antimicrob Agents Chemother. 2004 Feb;48(2):659-62. doi: 10.1128/AAC.48.2.659-662.2004.
4
In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.新型恶唑烷酮类药物DA-7867对近期需氧菌和厌氧菌临床分离株的体外活性
Antimicrob Agents Chemother. 2004 Jan;48(1):352-7. doi: 10.1128/AAC.48.1.352-357.2004.
5
Antimicrobial resistance among gram-positive organisms in the intensive care unit.重症监护病房革兰氏阳性菌的抗菌药物耐药性
Curr Opin Crit Care. 2003 Oct;9(5):403-12. doi: 10.1097/00075198-200310000-00011.
6
Linezolid in vitro: mechanism and antibacterial spectrum.利奈唑胺的体外作用机制及抗菌谱
J Antimicrob Chemother. 2003 May;51 Suppl 2:ii9-16. doi: 10.1093/jac/dkg249.
7
Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.耐利奈唑胺、耐万古霉素屎肠球菌的医院内传播。
N Engl J Med. 2002 Mar 14;346(11):867-9. doi: 10.1056/NEJM200203143461121.
8
Linezolid resistance in a clinical isolate of Staphylococcus aureus.金黄色葡萄球菌临床分离株中的利奈唑胺耐药性
Lancet. 2001 Jul 21;358(9277):207-8. doi: 10.1016/S0140-6736(01)05410-1.
9
Inhibition of group A streptococcus infection by carboxyfullerene.羧基富勒烯对A组链球菌感染的抑制作用。
Antimicrob Agents Chemother. 2001 Jun;45(6):1788-93. doi: 10.1128/AAC.45.6.1788-1793.2001.
10
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.耐万古霉素的屎肠球菌对利奈唑胺耐药导致的感染。
Lancet. 2001 Apr 14;357(9263):1179. doi: 10.1016/S0140-6736(00)04376-2.
Zotero 插件